51 results
8-K
EX-99.1
TPST
Tempest Therapeutics Inc
9 May 24
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
4:25pm
alone or with immune checkpoint inhibitors at the Society for Immunotherapy of Cancer (SITC) 2024 Spring Scientific Meeting. The presentation also
8-K
EX-99.1
TPST
Tempest Therapeutics Inc
19 Mar 24
Tempest Reports Year End 2023 Financial Results and Provides Business Update
4:10pm
with non-responders, following treatment with TPST-1120 and nivolumab.
Presented data at the Society for Immunotherapy of Cancer (SITC) 2023 Spring … at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting showing that in a diverse and treatment-refractory patient population
8-K
EX-99.1
bjtghwica
10 Aug 23
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
4:27pm
8-K
EX-99.1
2175nfkx9wz
10 May 23
Tempest Reports First Quarter 2023 Financial Results and Provides Business Update
4:21pm
8-K
EX-99.1
uo9q pvhimev
8 Nov 22
Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update
8:55am
8-K
EX-99.1
b8o2u
15 Aug 22
Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update
8:05am
8-K
EX-99.1
i2pi qa1rks
9 Jun 22
Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance
8:08am
8-K
EX-99.1
gjn44nkh
26 May 22
Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting
5:06pm
8-K
EX-99.1
ru5luj9
13 May 22
Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights
8:03am
8-K
EX-99.2
z7kuks7 9cjgy
2 May 22
Tempest Announces Private Placement Financing of $15 Million
8:02am
8-K
7oam c1gcub
2 May 22
Tempest Announces Private Placement Financing of $15 Million
8:02am
8-K
EX-99.1
1tk0udo3hf
29 Mar 22
Tempest Reports Year End 2021 Financial Results and Provides Corporate Highlights
4:41pm
8-K
EX-99.1
q27twvmvhrrnl
23 Dec 16
OvaScience Announces Business Update
12:00am